Esbriet (pirfenidone) seems to have diminishing therapeutic effect after six months of treatment and possibly no benefit after one year in idiopathic pulmonary fibrosis (IPF) patients with advanced disease, a Greek retrospective study shows. The study, “Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational…
Results from the RECAP clinical trial, which was conducted over five years, support the long-term safety of Esbriet (pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF). The study, “An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP),” was recently published in…
A small bacterial protein called R1R2 reduced fibrosis-promoting cells’ ability to go from the blood, where they normally reside, to lung tissue, a mouse study shows. The research, “R1R2 peptide ameliorates pulmonary fibrosis in mice through fibrocyte migration and differentiation,” was published in the journal PLOs One. Scientists…
Scientists at the University of Pennsylvania identified two populations of lung mesenchymal cells that may play a distinct role such in diseases as pulmonary fibrosis — one that seems to protect against disease and the other possibly promoting it when things go awry. Results suggest that future therapies targeting each cell type…
Research into key drivers of fibrosis will be used by a Singapore-funded biotechnology start-up, Enleofen Bio, to possibly develop first-in-class therapeutics for pulmonary fibrosis (PF) and other fibrosis-related diseases. The intellectual property that came from the work performed at two Singapore institutions, Duke-NUS Medical School (Duke-NUS) and National Heart Centre…
Doctors increasingly recognize nutrition as a key factor in improving overall function, exercise tolerance and quality of life in patients with pulmonary fibrosis and other lung diseases. With that in mind, a team has reviewed current literature and summarized nutritional goals for lung disease patients. The review titled “Nutrition…
The Australian company AdAlta will present new information on its idiopathic pulmonary fibrosis therapy AD-114 at the IPF Summit in Boston on Aug. 23. CEO Sam Cobb’s presentation will be titled “i-Bodies: A Novel Therapeutic Approach for IPF.” The three-day conference started Aug. 21. “IPF is a disease with high unmet clinical…
A Phase 2 trial testing the investigational therapy pamrevlumab (FG-3019) in patients with idiopathic pulmonary fibrosis (IPF) has shown positive and encouraging results, FibroGen, the drug’s developer, announced. In addition, combining pamrevlumab with the FDA-approved IPF therapies Esbriet (pirfenidone) and Ofev (nintedanib) was found to be safe. These results will be…
The protein vimentin triggers autoimmune reactions in people with idiopathic pulmonary fibrosis (IPF), and the intensity of the reactions correlates with the severity of the disease, according to a study. The findings underscore scientists’ belief that autoimmunity — the immune system attacking the body’s own cells instead of invaders — plays…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SM04646, a therapy developed by San Diego-based Samumed to treat idiopathic pulmonary fibrosis (IPF). This designation provides several benefits, including tax incentives, exemption from the FDA user fee and potential market exclusivity for seven years following approval. SM04646,…
Get regular updates to your inbox.
